Friday, September 20, 2024 11:04:33 AM
Looking good! upside is tremendous! $100.00 Target
always early!
$SMMT
always early!
$SMMT
Bullish
Recent SMMT News
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/06/2026 08:28:53 PM
- Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026 • Business Wire • 03/27/2026 12:15:00 PM
- Summit Therapeutics to Present at Upcoming Investor Conferences • Business Wire • 02/26/2026 11:45:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/23/2026 09:58:58 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/23/2026 09:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 09:07:53 PM
- Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025 • Business Wire • 02/23/2026 09:05:00 PM
- Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026 • Business Wire • 02/17/2026 10:05:00 PM
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 01/30/2026 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2026 12:35:03 PM
- Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy • Business Wire • 01/29/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2026 09:01:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 12:43:04 PM
- Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC) • Business Wire • 01/12/2026 11:15:00 AM
- Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC • Business Wire • 01/12/2026 11:00:00 AM
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 01/10/2026 01:16:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 11:52:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 11:39:57 PM
- Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference • Business Wire • 01/06/2026 12:30:00 PM
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 12/05/2025 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2025 02:23:15 PM
- Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China • Business Wire • 11/07/2025 02:00:00 PM
- Summit Therapeutics to Present at Upcoming Investor Conferences • Business Wire • 11/04/2025 12:00:00 PM
- Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025 • Business Wire • 10/31/2025 11:00:00 AM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 10/29/2025 09:10:42 PM
